Expertise in
41
conditions

Dr. Anju Vasudevan

Oncology
Florida Cancer Affiliates
3130 SW 32nd Ave, 
Ocala, FL 
Accepting New Patients
Expertise in
41
conditions
Florida Cancer Affiliates
3130 SW 32nd Ave, 
Ocala, FL 

Overview

Anju Vasudevan is an Oncologist practicing medicine in Ocala, Florida.

Dr. Vasudevan is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Lung Cancer, Inflammatory Breast Cancer, and Bone Marrow Aspiration.

Dr. Vasudevan is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 5 clinical trials. Dr. Vasudevan is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine

Fellowships

Buffalo General Hospital , Internal Medicine

Hospital Affiliations

AdventHealth Ocala
Marion Communtiy Hospital
Adventhealth Ocala

Languages Spoken

English
Hindi
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Florida Cancer Affiliates
3130 SW 32nd Ave, Ocala, FL 34474

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 4 Less Clinical Trials

22 Total Publications

Selective vulnerability of GABAergic neurons in chronic migraine.
Selective vulnerability of GABAergic neurons in chronic migraine.
Journal: The journal of headache and pain
Published: August 19, 2025
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Uf Health Surgical Specialists-Ocala Heath Brook

4730 SW 49th Rd, 
Ocala, FL 
 (1.8 miles away)
352-265-0535
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Hughes is an Oncologist practicing medicine in Ocala, Florida. Dr. Hughes is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Hughes is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

AHMG Oncology And Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (61.7 miles away)
321-732-5395
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Guru Sonpavde is an Oncologist practicing medicine in Orlando, Florida. Dr. Sonpavde is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Nephrectomy. Dr. Sonpavde is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

AdventHealth Medical Group Oncology & Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (61.7 miles away)
386-406-8205
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Socinski is an Oncologist practicing medicine in Orlando, Florida. Dr. Socinski is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Socinski is currently accepting new patients.

Frequently Asked Questions about Dr. Anju Vasudevan

How do I make an appointment with Dr. Anju Vasudevan?

You can book an appointment with Dr. Anju Vasudevan by calling their office at 352-732-4032. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anju Vasudevan a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anju Vasudevan is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anju Vasudevan specialize in?

While Dr. Anju Vasudevan is a Oncology, they have specific expertise in Paget Disease of the Breast, Breast Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anju Vasudevan participate in research or clinical trials?

Yes. Dr. Anju Vasudevan has published 22 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Anju Vasudevan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anju Vasudevan accept my insurance?

Dr. Anju Vasudevan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 352-732-4032 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vasudevan's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 33 Advanced Conditions
    View All 86 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile